US Patent

US8609701 — Pirfenidone treatment for patients with atypical liver function

Method of Use · Assigned to Intermune Inc · Expires 2029-04-22 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

Methods are provided for administering pirfenidone to patients with abnormal liver function biomarkers in response to pirfenidone administration.

USPTO Abstract

Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2067 —
U-1610 —
U-2069 —
U-2065 —

Patent Metadata

Patent number
US8609701
Jurisdiction
US
Classification
Method of Use
Expires
2029-04-22
Drug substance claim
No
Drug product claim
No
Assignee
Intermune Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.